CCT137690, also known as CCT-137690, is a small molecular inhibitor that has been studied for its potential therapeutic properties in the treatment of various types of cancers. This article will provide an overview of CCT137690, including its chemical name, molecular formula, formula weight, CAS number, top ten keywords from Google and synonyms, health benefits, potential effects, product mechanism, safety, side effects, and dosing information.
Chemical Name: The chemical name of CCT137690 is N-(3-((2-(2,6-dichlorophenyl)thiazol-4-yl)amino)pyridin-2-yl)-4-methylbenzenesulfonamide.
Molecular Formula: The molecular formula of CCT137690 is C22H16Cl2N4O2S2.
Formula Weight: The formula weight of CCT137690 is 510.42 g/mol.
CAS No: The CAS number of CCT137690 is 1095382-05-0.
Top Ten Keywords from Google and Synonyms:
Synonyms for CCT137690 include N-(3-((2-(2,6-dichlorophenyl)thiazol-4-yl)amino)pyridin-2-yl)-4-methylbenzenesulfonamide, CCT-137690, and 1095382-05-0.
Health Benefits of this Product: CCT137690 has shown potential as a cancer therapy agent. It functions as an inhibitor of protein kinases, which are enzymes involved in a variety of cellular signaling pathways. By inhibiting these enzymes, CCT137690 can interfere with cell cycle progression and induce apoptosis, or programmed cell death, in cancer cells. Additionally, studies have suggested that CCT137690 may be effective against drug-resistant cancer cells.
Potential Effects: The potential effects of CCT137690 on cancer cells include inhibition of cell division, induction of apoptosis, and prevention of metastasis. In preclinical studies, CCT137690 has demonstrated activity against multiple types of cancer, including breast cancer, lung cancer, melanoma, and leukemia. However, additional research is needed to determine the full range of potential effects of CCT137690 on cancer cells.
Product Mechanism: CCT137690 functions as an inhibitor of protein kinases, specifically checkpoint kinase 1 (Chk1) and polo-like kinase 1 (Plk1). Chk1 and Plk1 are enzymes involved in the regulation of cell cycle progression, DNA damage response, and other cellular processes. By inhibiting these enzymes, CCT137690 interferes with cell cycle progression and induces apoptosis in cancer cells.
Safety: The safety profile of CCT137690 has not been extensively studied in humans. However, preclinical studies have suggested that the compound has low toxicity and is generally well-tolerated. Like all medications, CCT137690 may cause side effects in some individuals.
Side Effects: The potential side effects of CCT137690 are not well-defined, as the compound has not been extensively studied in humans. However, preclinical studies have suggested that the compound has low toxicity and is generally well-tolerated. Common side effects of kinase inhibitors include fatigue, nausea, and diarrhea.
Dosing Information: The optimal dosing regimen of CCT137690 has not been established. Preclinical studies have suggested that the compound is most effective when administered in combination with other cancer therapies, such as chemotherapy or radiation therapy. The appropriate dose and duration of treatment with CCT137690 may vary depending on the type and stage of cancer being treated.
Conclusion: In conclusion, CCT137690 is a small molecular inhibitor that has shown promise as a cancer therapy agent in preclinical studies. The compound functions by inhibiting protein kinases involved in cell cycle progression and inducing apoptosis in cancer cells. Although the safety profile and optimal dosing regimen of CCT137690 have yet to be established, the compound may offer a new approach to the treatment of various types of cancers, particularly in cases where traditional therapies have been ineffective.
